SOLUBLE INTERLEUKIN-2 RECEPTOR LEVELS IN CYTOMEGALOVIRUS DISEASE AND GRAFT-VERSUS-HOST DISEASE AFTER T-LYMPHOCYTE DEPLETED BONE-MARROW TRANSPLANTATION FOR HEMATOLOGICAL NEOPLASIAS

被引：8

作者：

ENGELHARD, D

NAGLER, A

SINGER, R

BARAK, V

机构：

[1] Department of Pediatrics, Hadassah University Hospital

[2] Bone Marrow Transplantation and Hadassah University Hospital

[3] Oncology-Immunology Laboratory for Tumor Diagnosis, Hadassah University Hospital

来源：

LEUKEMIA & LYMPHOMA | 1994年 / 12卷 / 3-4期

关键词：

CYTOMEGALOVIRUS DISEASE; GRAFT VERSUS HOST DISEASE; SOLUBLE INTERLEUKIN-2 RECEPTOR; CYTOKINES; BONE MARROW TRANSPLANTATION;

D O I：

10.3109/10428199409059599

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In recent years, the soluble Interleukin-2 Receptor (sIL-2R) has gained recognition as a valuable marker of in vivo activated immune functions in a variety of diseases. We studied sIL-2R levels in patients with cytomegalovirus (CMV) disease, and/or graft versus host disease (GVHD) following bone marrow transplantation (BMT). Our study included 36 patients after T-cell depleted allogeneic BMT and 11 healthy controls. Mean sIL-2R serum levels were significantly higher after BMT than before (1273 u/ml vs. 629 u/ml, respectively, p < 0.007). In the patients who developed CMV disease, with or without GVHD, mean sIL-2R levels increased significantly (2866 u/ml p < 0.004); there was a drop after recovery (1949 u/ml), but not a return to pre-CMV onset levels. Similar elevated sIL-2R levels were found in patients during CMV disease only, GVHD. only, or both. In patients who developed GVHD, sIL-2R levels were positively correlated with the severity of GVHD (Pearson's correlation coefficient .8322, p < 0.003). We conclude that sIL-2R may serve as a valuable nonspecific marker for the presence of CMV disease and severity of GVHD following T-lymphocyte depleted BMT.

引用

页码：273 / 280

页数：8

共 26 条

[1]

Kelso A., Cytokines: structure, function and synthesis, Current Opinion in Immunol., 2, 2, (1989)

[2]

Paul W., Pleiotropy and redundancy: T Cell-derived lymphokines in the immune response, Cell, 57, (1989)

[3]

Loughnan M.S., Nossal G.J.V., Interleukins 4 and 5 control expression of IL-2 receptor on murine B cells through independent induction of its two chains, Nature, 340, (1989)

[4]

Hatakeyama M., Tsudo M., Minamoto S., Kono T., Doi T., Miyata M., Miyasak T., Taniguchi T., Interleukin-2 receptor beta-chain gene

[5]

generation of three receptor forms by cloned human alpha and beta chain cDNA's, Science, 244, (1989)

[6]

Crabtree G.R., Contingent genetic regulatory events in T lymphocyte activation, Science, 243, (1989)

[7]

Rubin L.A., Jay G., Nelson D.L., The released interleukin-2 receptor binds interleukin 2 efficiently, J. Immunol., 137, (1986)

[8]

Nelson D.L., Soluble interleukin-2 receptors: analysis in normal individuals and in certain disease states, Fed. Proc., 45, (1986)

[9]

Wagner D.K., Kiwanuka J., Edwards B.K., Rubin L.A., Nelson D.L., Magrath I.T., Serum Interleukin-2 receptor levels in patients with undifferentiated and lymphoblastic lymphomas: Correlation with survival, J. Clin. Oncol., 5, (1987)

[10]

Barak V., Ginsburg M., Kalichman I., Polliack A., Serum sIL-2R levels are associated with clinical disease status and pathological grade in non Hodgkin's lymphoma and chronic lymphocytic leukemia, Leukemia and Lymphoma, 7, (1992)

← 1 2 3 →